incretin receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-04. Anything still debated is marked as such rather than presented as settled.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids engineered from the native glucose-dependent insulinotropic polypeptide sequence. Its structure incorporates several non-natural residues and a C-terminal segment derived from glucagon-like peptide-1, together with a C20 fatty diacid moiety attached through a linker. The lipophilic side chain promotes binding to serum albumin, which slows renal clearance after administration. The compound is classified as a dual incretin receptor agonist and is supplied as a lyophilized powder for reconstitution or as a preformulated solution, depending on the presentation.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Approximate composition of the free peptide |
| Molecular weight | Approximately 4813 Da | Calculated for the free base |
| Structural class | Synthetic linear peptide | 39 residues with modified backbone |
| Solubility | Soluble in water and polar solvents | Behavior of the lyophilized solid |
| Typical storage temperature | -20 degrees Celsius or below | Solid form, protected from light |
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
A chloroplast ( KLOR-ə-plast, -plahst) is a type of organelle known as a plastid that conducts photosynthesis mostly in plant and algal cells. Chloroplasts have a high concentration of chlorophyll pigments which capture the energy from sunlight, convert it to chemical energy and decompose water to release oxygen. The chemical energy created is then used to make sugar and other organic molecules from carbon dioxide in the Calvin cycle. Chloroplasts carry out a number of other functions, including fatty acid synthesis, amino acid synthesis, and immune response in plants. The number of chloroplasts per cell varies from one, in some unicellular algae, up to 100 in plants like Arabidopsis and wheat. Chloroplasts are highly dynamic - they circulate and are moved around within cells. Their behavior is strongly influenced by environmental factors, such as light color and intensity. Chlroplasts are thought to have evolved from an ancient photosynthetic cyanobacterium ancestor that was engulfed by an early eukaryotic cell. Because of their endosymbiotic origins, chloroplasts, like mitochondria, contain their own DNA separate from that of the cell nucleus. Chloroplasts multiply by division, and cannot be made anew by the plant cell, but must be inherited by each daughter cell during cell division.
But I realised that wasn't the truth." Upon Ceaușescu's return from Iran on the evening of 20 December, the situation became even more tense, and he gave a televised speech from the TV studio inside the Central Committee Building (CC Building) in which he spoke about the events at Timișoara in terms of an "interference of foreign forces in Romania's internal affairs" and an "external aggression on Romania's sovereignty." The country, which had no information about the Timișoara events from the national media, heard about the Timișoara revolt from Western radio stations like Voice of America and Radio Free Europe, and by word of mouth. A mass meeting was staged for the next day, 21 December, which, according to the official media, was presented as a "spontaneous movement of support for Ceaușescu," emulating the 1968 meeting in which Ceaușescu had spoken against the invasion of Czechoslovakia by Warsaw Pact forces.
==== April 2008 norovirus ==== In 2008, Chipotle was implicated in a norovirus outbreak in Kent, Ohio, where over 400 people became ill after eating at a Chipotle restaurant. Officials at the Ohio Department of Health said that the outbreak was caused by Norovirus Genotype G2. Many of the victims were students at Kent State University. The initial source of the outbreak was never found.
== Catabolic hormones == There are many signals that control catabolism. Most of the known signals are hormones and the molecules involved in metabolism itself. Endocrinologists have traditionally classified many of the hormones as anabolic or catabolic, depending on which part of metabolism they stimulate. The so-called classic catabolic hormones known since the early 20th century are cortisol, glucagon, and adrenaline (and other catecholamines). In recent decades, many more hormones with at least some catabolic effects have been discovered, including cytokines, orexin (known as hypocretin), and melatonin.
The primary medical treatment of acromegaly is to use somatostatin analogues – octreotide (Sandostatin) or lanreotide (Somatuline). Somatostatin analogues are also sometimes used to shrink large tumors before surgery. Because octreotide inhibits gastrointestinal and pancreatic function, long-term use causes digestive problems such as loose stools, nausea, and gas in one-third of people. In addition, approximately 25 percent of people with acromegaly develop gallstones, which are usually asymptomatic. In some cases, octreotide treatment can cause diabetes because somatostatin and its analogues can inhibit the release of insulin. With an aggressive adenoma that is not able to be operated on, there may be a resistance to octreotide in which case a second-generation SSA, pasireotide, may be used for tumor control. However, insulin and glucose levels should be carefully monitored as pasireotide has been associated with hyperglycemia by reducing insulin secretion.
Sources: en.wikipedia.org
2 NpF3 + 3 Ba → 2 Np + 3 BaF2 By weight, neptunium-237 discharges are about 5% as great as plutonium discharges and about 0.05% of spent nuclear fuel discharges. However, even this fraction still amounts to more than fifty tons per year globally.
The activated PPAR/RXR heterodimer binds to peroxisome proliferator hormone response elements upstream of target genes in complex with a number of coactivators such as nuclear receptor coactivator 1 and CREB binding protein, this causes upregulation of genes (for a full list see PPARγ):
Standard reuptake inhibitors are believed to act simply as competitive substrates that work by binding directly to the plasmalemma transporter of the neurotransmitter in question. They occupy the transporter in place of the respective neurotransmitter and competitively block it from being transported from the nerve terminal or synapse into the pre-synaptic neuron. With high enough doses, occupation becomes as much as 80–90%. At this level of inhibition, the transporter will be considerably less efficient at removing excess d from the synapse and this causes a substantial increase in the extracellular concentrations of the neurotransmitter and therefore an increase in overall neurotransmission.
The first of these three means that the contact quadrilateral WXYZ is an orthodiagonal quadrilateral. A tangential quadrilateral is bicentric if and only if its inradius is greater than that of any other tangential quadrilateral having the same sequence of side lengths.
Sources: en.wikipedia.org
III (stylized as (III)) is the third studio album by Canadian electronic music duo Crystal Castles, released on November 7, 2012, by Fiction Records and Polydor Records. Production was handled by Ethan Kath, with additional production by Jacknife Lee. III is the last Crystal Castles album with vocalist Alice Glass before her departure in 2014, and is also their last eponymous album, as the band's 2016 album is titled Amnesty (I) instead of (IV) or Crystal Castles. Glass continued the series on her own by including "IV" into the title of her 2022 debut album Prey//IV.
Iceland, on the contrary, has a rather low prevalence of 1 per 100,000, despite the fact that Icelanders as a people are descended from the early Germanic tribes of Scandinavia which also gave rise to the Swedes; all cases with the exception of one going back nearly two centuries having derived from the offspring of a couple living early in the 19th century. Finland, as well, has a low incidence of only 2.2 per 100,000 people. Until the discovery of a genetic test, statistics could only include clinical diagnosis based on physical symptoms and a family history of HD, excluding those who died of other causes before diagnosis. These cases can now be included in statistics; and, as the test becomes more widely available, estimates of the prevalence and incidence of the disorder are likely to increase.
== Etymology == The word muscle comes from Latin musculus, diminutive of mus meaning mouse, because the appearance of the flexed biceps resembles the back of a mouse. The same etymology is found in Greek, in which μῦς, mȳs, means both "mouse" and "muscle".
The stolon is ready to harvest two to three months after planting. It must be harvested before flowering. Harvesting the stolon is done by manual labor. For this step, the field is not drained. The stolon is pulled out of the water by pulling and shaking the young leaves in the shallow water. The first leaves and flowers can be harvested three months after planting. Flowers can be picked every two days during summer and every three days during the colder season. Four months after planting, the production of flowers has its climax. The harvest of flowers is usually done by hand for three to four months. Seeds and seed pods can be harvested when they turn black four to eight months after planting. After sun drying for two to three days, they are processed by mechanical tools to separate seed coats and embryos. The rhizomes mature to a suitable stage for eating in approximately six to nine months. Early varieties are harvested in July until September and late varieties from October until March, after the ponds or fields are drained. The large, starch-rich rhizomes are easy to dig out of the drained soil. In small-scale production, they are harvested by hand using fork-like tools. In Japan and on bigger farms, manual labour harvesting is fully replaced by machines.
==== Amnion ==== The amnion is avascular, meaning it does not contain its own blood vessels. Therefore, it must obtain necessary nutrients and oxygen from nearby chorionic and amniotic fluid, and fetal surface vessels. The amnion is characterised by cuboidal and columnar epithelial layers. The columnar cells are located in the vicinity of the placenta, whereas the cuboidal cells are found in the periphery. During early pregnancy, the amnionic epithelium is sparsely covered in microvilli, which increase in number throughout pregnancy. The function of this microvillous surface is associated with a densely-packed glycocalix with anionic binding sites; these are thought to be involved with intra-amnionic lipid synthesis. This amnionic epithelium is connected to a basement membrane, which is then attached by filaments to a connective tissue layer.
Sources: en.wikipedia.org
It is a synthetic linear peptide that acts as a dual agonist at the GIP and GLP-1 receptors. It combines a modified incretin backbone with a fatty diacid side chain that extends its circulation time. It is not a small-molecule drug and is not orally absorbed in its native form.
Single-receptor agents act predominantly at GLP-1R. Tirzepatide retains activity at GIPR, which is expressed in pancreatic islets, adipose tissue, and the central nervous system. The contribution of each receptor to the overall response is still an area of active study, and the relative weight of GIPR signaling in humans is not fully settled.
The fatty diacid moiety binds serum albumin, which reduces renal filtration of the active peptide. Additional resistance to enzymatic breakdown comes from non-natural residues in the backbone. Together these features produce an apparent half-life of about five days and permit weekly dosing intervals.
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.